Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) Short Interest Update

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) was the target of a significant decrease in short interest in July. As of July 31st, there was short interest totalling 38,900 shares, a decrease of 23.6% from the June 30th total of 50,900 shares. Based on an average daily trading volume, of 42,900 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.3% of the shares of the stock are sold short.

NASDAQ:ORMP traded up $0.06 during trading hours on Tuesday, reaching $3.39. 14,200 shares of the company were exchanged, compared to its average volume of 51,646. The firm has a market capitalization of $58.74 million, a P/E ratio of -3.94 and a beta of 1.34. Oramed Pharmaceuticals has a 1-year low of $2.78 and a 1-year high of $5.32. The firm has a 50 day moving average of $3.52.

Oramed Pharmaceuticals (NASDAQ:ORMP) last released its earnings results on Wednesday, July 10th. The biotechnology company reported ($0.23) earnings per share for the quarter, hitting the consensus estimate of ($0.23). Oramed Pharmaceuticals had a negative return on equity of 56.15% and a negative net margin of 568.43%. The firm had revenue of $0.68 million during the quarter, compared to analysts’ expectations of $0.71 million. Equities research analysts anticipate that Oramed Pharmaceuticals will post -0.98 earnings per share for the current fiscal year.

A number of equities research analysts recently issued reports on the company. ValuEngine raised Oramed Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. HC Wainwright reissued a “buy” rating on shares of Oramed Pharmaceuticals in a research report on Wednesday, June 19th.

In related news, Director Leonard Sank purchased 20,000 shares of Oramed Pharmaceuticals stock in a transaction that occurred on Tuesday, July 16th. The shares were acquired at an average price of $3.47 per share, with a total value of $69,400.00. Following the completion of the transaction, the director now directly owns 315,482 shares of the company’s stock, valued at approximately $1,094,722.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have purchased 25,817 shares of company stock worth $91,009 in the last three months. 20.50% of the stock is currently owned by company insiders.

An institutional investor recently raised its position in Oramed Pharmaceuticals stock. BlackRock Inc. boosted its holdings in shares of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) by 137.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 69,343 shares of the biotechnology company’s stock after purchasing an additional 40,114 shares during the period. BlackRock Inc. owned about 0.40% of Oramed Pharmaceuticals worth $208,000 at the end of the most recent quarter. 6.15% of the stock is owned by institutional investors.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.

Recommended Story: Why investors pay attention to retained earnings

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit